Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
2-phase
7%
Adult Patients
14%
Airway Epithelium
7%
Allergen Immunotherapy
8%
Alternative Splicing
7%
Angioedema Attack
23%
Asthma
25%
Asthma Outcomes
10%
Atopic Dermatitis
42%
Bazooka
7%
Bile Duct Ligation
7%
Biomarker Candidates
7%
Cardiac Valves
7%
CD8+
10%
Chronic Itch
13%
Chronic Pruritus
11%
Chronic Spontaneous Urticaria
9%
Clear or Almost Clear Skin
10%
Clinical Trials
13%
Cockroach
9%
COVID-19
10%
Dendritic Cells
11%
Dermatological Diseases
11%
Difelikefalin
16%
Distal Nephron
14%
Drosophila Development
7%
Dupilumab
50%
Dysregulation
18%
Elastogenesis
7%
Epithelial Cells
8%
Epithelial Sodium Channel (ENaC)
16%
Flow Effect
12%
Gene Expression
14%
Health-related Quality of Life
8%
Hepatocytes
11%
Hereditary Angioedema
47%
Hereditary Angioedema with Normal C1 Inhibitor
7%
Homeostasis
10%
Human Pluripotent Stem Cells (hPSCs)
9%
Human Skin
11%
Immune System
11%
Inflammation
8%
Intercalated Cells
15%
Interleukin-4 (IL-4)
10%
International Dermatology Outcome Measures
7%
Itch
100%
K+ Secretion
16%
KCNMA1
7%
Kidney
12%
Lanadelumab
11%
Lipid Nanoparticles
12%
Long-term Prophylaxis
15%
Lung
23%
Lung Organoids
11%
Macrophages
11%
Mast Cell Activation Syndrome
7%
Mast Cells
9%
Moderate to Severe
9%
Moderate-to-severe Atopic Dermatitis
18%
Monocytes/macrophages
9%
Mouse Kidney
8%
MRNA Vaccine
8%
Neuroimmune
11%
Neuroimmune Interactions
10%
Neuroimmunology
12%
Notalgia Paresthetica
15%
Notch Signaling
7%
Numeric Rating Scale
26%
Numerical Rating Scale
11%
Older Adults
15%
On-demand Treatment
13%
Organoids
18%
Phase 3 Trial
8%
Phase II Trial
8%
Placebo
37%
Principal Cells
10%
Prurigo Nodularis
56%
Pruritic
10%
Pruritus
64%
Quality of Life
9%
Randomized Clinical Trial
7%
Randomized Controlled Trial
7%
Sarcoidosis
7%
SARS-CoV-2 Infection
8%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
25%
Single-cell RNA Sequencing (scRNA-seq)
17%
Skin Diseases
10%
Skin Lesions
10%
Skin Pain
12%
Spatial Transcriptomics
18%
Survival Outcomes
13%
Symptom Burden
10%
T Cell Response
9%
T Cells
15%
Therapeutic Development
8%
Therapeutic Target
10%
Tumor
13%
Tumor Microenvironment
10%
Type 2 Inflammation
14%
Upadacitinib
11%
Immunology and Microbiology
Adaptive Immune System
9%
Agonist
8%
Airway
16%
Allergen
19%
Allograft
6%
Alveolar Macrophage
7%
Antigen
5%
Asthma
21%
Atopic Dermatitis
43%
Autonomic Nervous System
7%
Basophil
9%
C1-Inhibitor
7%
Calcitonin Gene Related Peptide
6%
Cancer Immunotherapy
5%
CCL2
5%
CD8
8%
Cell Activation
7%
Central Nervous System
7%
Chimeric Antigen Receptor T-Cell
5%
Chromatin
6%
Cytokine
22%
Cytotoxic T-Cell
8%
Dendritic Cell
14%
Dermatitis
15%
Dupilumab
12%
Endothelial Cells
8%
Epitope
5%
Fibroblast
21%
Gene Expression
12%
Gene Expression Assay
12%
Hereditary Angioedema
41%
Homeostasis
23%
Immune Response
14%
Immune System
10%
Immunocompetent Cell
13%
Immunosuppressive Drug
9%
Immunotherapy
21%
In Vitro
12%
Infection
15%
Infectious Agent
16%
Infectious Disease
14%
Inflammation
29%
Influenzavirus A
6%
Innate Immune System
6%
Innate Lymphoid Cell
9%
interferon
8%
Interleukin 4
9%
Keratinocyte
5%
Kinase
6%
Lanadelumab
11%
Lineages
8%
Lipid Nanoparticles
15%
Lung
32%
Macrophage
23%
Mast Cell
5%
Merkel Cell
8%
Monocyte
11%
Mouse Model
6%
Mucosal Immunology
7%
Myeloid
13%
Myelopoiesis
8%
Natural Killer Cell
5%
Neurological System
13%
Phosphotransferase
6%
Proinflammatory Cytokine
8%
Ribonucleic Acid
17%
RNA Sequence
20%
Sarcoidosis
7%
Secretion (Process)
5%
Sensory System
7%
Severe Acute Respiratory Syndrome Coronavirus 2
28%
Signal Transduction
7%
Systemic Inflammation
5%
T Cell
25%
Therapeutic Target
12%
Transcriptomics
17%
Tumor Necrosis Factor
7%
Tumor-Associated Macrophage
6%
Viral Disease
8%
Medicine and Dentistry
Activation Syndrome
7%
Adverse Event
5%
Alternative RNA Splicing
7%
Anaplastic Thyroid Carcinoma
7%
Apolipoprotein E
7%
Asthma
28%
Atopic Dermatitis
36%
Bile Duct Ligation
7%
BK Channel
5%
Cell Activation
7%
Chronic Urticaria
7%
Clinical Trial
15%
Collecting Duct
8%
Comorbidity
6%
COVID-19
6%
Dermatitis
5%
Dermatological Agent
10%
Dermatology
13%
Difelikefalin
8%
Diseases
34%
Dupilumab
32%
Elastin
6%
Endothelial Cell
9%
Extracellular Matrix
5%
Fibroblast
8%
Gene Expression Profiling
8%
Hereditary Angioedema
19%
Immunosuppressive Drug
5%
Immunotherapy
8%
Inflammation
17%
Lung
5%
Mast Cell
12%
Messenger RNA
8%
Mineralocorticoid Receptor
7%
Morbidity
6%
Nephron
13%
Numeric Rating Scale
11%
Overall Survival
5%
Pathogenesis
9%
Pathophysiology
10%
Placebo
20%
Posttraumatic Stress Disorder
7%
Potassium Ion
12%
Protein Expression
5%
Prurigo nodularis
44%
Pruritus
91%
Quality of Life
18%
Receptor Blocking
7%
RNA Sequence
11%
Secretion (Process)
10%
Sensation
7%
Skin Defect
10%
Skin Pain
6%
Sodium Channel
10%
Spatial Transcriptomics
7%
Targeted Therapy
6%
Therapeutic Target
5%